VIGL Overview
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading chart...
The current price of VIGL is 0 USD — it has increased 0
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
Wall Street analysts forecast VIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIGL is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Vigil Neuroscience Inc revenue for the last quarter amounts to -27.49M USD, increased 22.30
Vigil Neuroscience Inc. EPS for the last quarter amounts to -20548000.00 USD, increased 32.51
Vigil Neuroscience Inc (VIGL) has 69 emplpoyees as of June 13 2026.
Today VIGL has the market capitalization of 168.38M USD.
